Idarucizumab, a specific dabigatran reversal agentWANG Ran-ran, YU Huan, ZHENG Ying-li, GU Zhi-chun361-365
Valuing model of new drug R&D project based on neural network and real optionsXUE Yong-gang, ZHANG Ming-li370-375,383
Analyzing the influence of implementing new regulations on clinical vaccine trialsLI Ming-qiang, L(U) Bang-jun, QIN Yan-xiang376-379
Ability standards for institution construction of drug inspectingGAO Zhi-feng, LIN Lan, MEN Ying-xuan380-383
Investigation of drug control institutes' attitude on the national assessment programsWANG Lei, CHEN Yu-wen, HUA Lian384-388
Technical requirements of reference standards for registration of chemical drugsREN Lian-jie, ZHANG Ning, CHEN Zhen389-394,404
Modern phenotypic drug screening, a feasible strategy for drug discoveryWANG Yue-hua, DU Guan-hua395-404
Pharmacokinetics and pharmacodynamics of atorvastatin calcium tablets in Beagle dogs evaluated by enzyme activity and LC-MS/MS methods王晴, 王晶, 邵玉凤, 韩江彬, 盖芸芸, 沙春洁, 邓雨薇, 刘万卉405-409
Chemical properties and immunogenicity of type 1 pneumococcal polysaccharide conjugation胡浩, 朱学喆, 李献林, 罗树权, 李阿妮, 刘佳, 刘爱萍, 赵志强, 谢贵林410-417,424